Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Mar 28, 2020
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-new-analysis-further-showed-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-new-analysis-further-showed-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment-0